| Literature DB >> 34067942 |
Miguel Díaz-Guerrero1, Meztlli O Gaytán1, Eduardo Soto1, Norma Espinosa1, Elizabeth García-Gómez2, Arely Marcos-Vilchis1, Angel Andrade3, Bertha González-Pedrajo1.
Abstract
The type III secretion system (T3SS) is a complex molecular device used by several pathogenic bacteria to translocate effector proteins directly into eukaryotic host cells. One remarkable feature of the T3SS is its ability to secrete different categories of proteins in a hierarchical manner, to ensure proper assembly and timely delivery of effectors into target cells. In enteropathogenic Escherichia coli, the substrate specificity switch from translocator to effector secretion is regulated by a gatekeeper complex composed of SepL, SepD, and CesL proteins. Here, we report a characterization of the CesL protein using biochemical and genetic approaches. We investigated discrepancies in the phenotype among different cesL deletion mutants and showed that CesL is indeed essential for translocator secretion and to prevent premature effector secretion. We also demonstrated that CesL engages in pairwise interactions with both SepL and SepD. Furthermore, while association of SepL to the membrane does not depended on CesL, the absence of any of the proteins forming the heterotrimeric complex compromised the intracellular stability of each component. In addition, we found that CesL interacts with the cytoplasmic domains of the export gate components EscU and EscV. We propose a mechanism for substrate secretion regulation governed by the SepL/SepD/CesL complex.Entities:
Keywords: CesL; EPEC; gatekeeper complex; secretion hierarchy; type III secretion system
Year: 2021 PMID: 34067942 PMCID: PMC8152094 DOI: 10.3390/microorganisms9051047
Source DB: PubMed Journal: Microorganisms ISSN: 2076-2607
Strains and plasmids used in this study.
| Strain or Plasmid | Description 1 | Reference or Source |
|---|---|---|
|
| ||
| TOP10 | Strain used for cloning; Smr | Invitrogen |
| XL1-Blue | Strain used for plasmid propagation and DNA purification; Tcr | Stratagene |
| BL21 (DE3) pLysS | Strain used for expression of pET19b based plasmids; Cmr | Novagen |
| SU202 | Reporter strain for LexA-based two-hybrid assays; Cmr Kmr | [ |
| EPEC E2348/69 | Wild-type EPEC strain O127:H6; Smr | [ |
| Δ | E2348/69 carrying an in-frame deletion of | [ |
| Δ | E2348/69 | This study |
| Δ | E2348/69 | This study |
| Δ | Derived from Δ | This study |
| Δ | E2348/69 carrying an in-frame deletion of | Gift of the Puente JL Lab |
| Δ | E2348/69 carrying an in-frame deletion of | Gift of the Puente JL Lab |
| Δ | E2348/69 | This study |
| Δ | E2348/69 | This study |
| E2348/69 expressing 3×FLAG-tagged SepL; Smr Kmr | [ | |
| E2348/69 expressing 3×FLAG-tagged SepL and carrying a deletion of | This study | |
| E2348/69 expressing 3×FLAG-tagged SepL and carrying an in-frame deletion of | This study | |
| E2348/69 expressing 3×FLAG-tagged | This study | |
| E2348/69 expressing 3×FLAG-tagged CesL and carrying an in-frame deletion of | This study | |
| E2348/69 expressing 3×FLAG-tagged CesL and carrying an in-frame deletion of | This study | |
|
| ||
| SJW1368 | Strain used for expression of pTrc99A-based plasmids; flagellar master operon mutant, Δ( | [ |
| JR501 | Strain used to convert | [ |
|
| ||
| PJ69-4a/ | [ | |
| pKD4 | Template plasmid for amplification of the kanamycin resistance cassette | [ |
| pKD46 | λ-Red recombinase system plasmid with an inducible | [ |
| pSUB11 | Template plasmid for amplification of the 3x-FLAG epitope and kanamycin resistant cassette; Apr Kmr | [ |
| pFLP2 | Plasmid used for expression of the Flp recombinase; Apr | [ |
| pTrc99A | Expression vector with an inducible | Amersham-Pharmacia |
| pTrc99A_FF4 | Modified pTrc99A expression vector with an inducible | [ |
| pMTcL | This study | |
| pMTHcL | This study | |
| pATpD | [ | |
| pMTpL | [ | |
| pMTBISpDcL | [ | |
| pMTBISpDpL | This study | |
| pMTBISpLcL | This study | |
| pMTBISpLpD | This study | |
| pMTBISpDpLΔ75 | This study | |
| pET19b | Plasmid used for expression of His tagged proteins under the control of an inducible T7 promoter, Apr | Novagen |
| pAEpD | This study | |
| pMEcL | [ | |
| pMEpL | This study | |
| pMEpLΔ75 | This study | |
| pMEpLΔ81-94 | This study | |
| pKEeDN | [ | |
| pKEeVC | [ | |
| pJEeUC | [ | |
| pACTrc | pACYC184 expression vector derivative; pTrc promoter, p15A origin of replication, | [ |
| pMATpD | This study | |
| pMATpL | [ | |
| pMATpLΔ30 | This study | |
| pMATpLΔ81-94 | This study | |
| pMATcL | This study | |
| pMATcL2HA | This study | |
| pMATcLCΔ10 | This study | |
| pMAL-c2X | Plasmid used for expression of MBP-tagged proteins under the control of the | New England Biolabs |
| pMLcL | This study | |
| pMLcLCΔ10 | This study | |
| pTOPO-2HA | pCR2.1-TOPO derivative carrying | [ |
| pMHcL | This study | |
| pJHeH | [ | |
| pGBKT7 | Y2H vector containing GAL4 DNA binding domain; | Clontech |
| pOGBpD | This study | |
| pGBKT7-53 | pGBKT7 encoding a fusion of the GAL4 DNA binding domain with murine p53 | Clontech |
| pGBKT7-Lam | pGBKT7 encoding a fusion of the GAL4 DNA binding domain with human lamin C | Clontech |
| pGADT7 | Y2H vector containing GAL4 activation domain; | Clontech |
| pMGADpL | This study | |
| pOGADpLΔ81-94 | This study | |
| pMGADcL | This study | |
| pMGADcLCΔ10 | This study | |
| pGADT7-T | pGADT7 encoding a fusion of the GAL4 activation domain with the simian virus 40 (SV40) large T antigen | Clontech |
| pSR658 | Encodes LexA DNA binding domain (WT). ColE1 origin of replication; Tcr | Gift of the Puente JL Lab |
| pMR58cL | This study | |
| pMR58pD | This study | |
| pMR58tir | This study | |
| pSR659 | Encodes LexA DNA binding domain (Mut). p15A origin of replication; Apr | Gift of the Puente JL Lab |
| pMR59cT | This study | |
| pMR59pD | This study | |
| pMR59pL | This study | |
1 Sm: streptomycin; Km: kanamycin; Cm: chloramphenicol; Tc: tetracycline.
Oligonucleotides used in this study.
| Oligonucleotide | Sequence 5′ to 3′ |
|---|---|
| delcesLSRS_Fw | AACCGTGTTGAAATTGATTTTAATGGGTTTTCTTTTTTTATTGAAATAATTGATAATAATGTGTAGGCTGGAGCTGCTTCGAAGTTCCTATA |
| delcesL_Rv | ATTTAAGAGTTTATTCATGATGTCATCCTGCGAACGCGCTCAATAATCTGAATATCCTCCTTAGTTCCTA |
| delcesL_Fw | TTTTAGTTAAAAGAAATGTTGAAGAGTTTTTAAGATTGTTGGGAAATGATGTGTAGGCTGGAGCTGCTTC |
| sepL-3FLAG_Fw | ATACATTATTAATGATTGGTAAAGTGATAGATTATAAGGAGGATGTTATGGACTACAAAGACCATGACGG |
| sepL-3FLAG_Rv | CCTCTTCATAATCTTTCTTAGCATGACAAAAACTATAAAAAAAAACAATAATGAATATCCTCCTTAGTTC |
| cesL-3FLAG_Fw | GAATACTTTTCAACAGCATGTGCAGATTATTGAGCGCGTTCGCAGGATGACATCAGACTACAAAGACCATGACGG |
| cesL-3FLAG_Rv | AAGATCGTGATATGACTCTGCTTTTTTAAATATATTTAAGAGTTTATTCATATGAATATCCTCCTTAGTTC |
| sepLNdeI_Fw | AGTTTCATATGGCTAATGGTATTG |
| sepLNdeIΔ30_Fw | GCAATTACATATGCAAAAAAATTC |
| sepLNdeΔ75_Fw | GAATTTAATCATATGCCCGCATCT |
| sepLBamHI_Rv | CTATAAAAAAAAGGATCCTCACAT |
| sepLΔ81-94-A_Rv | ACCGATAGTGATAAAATAAAAGAA |
| sepLΔ81-94-B_Fw | ATCACTATCGGTTGTCGTGCCTTC |
| cesLBamHI_Fw | AGCCTGGGATCCAATCTTTTAGT |
| cesLHindIII_Rv | ATTTAAAAGCTTATTCATGATGTC |
| cesLMalPstI_Rv | ACGCGCTGCAGTTACTGCACATGC |
| cesLNdeI_Fw | AGAGCCTGCATATGAATCTTTTAG |
| cesLCΔ10_Rv | GGATCCTCACTGCACATGCTGTTG |
| cesLHA_Fw | TACTGTAAGCTTTATCCAATACGC |
| cesLHA_Rv | TTAAGAGTTCTCGAGTGATGTCAT |
| sepDXhoI_Fw | ACGGGTACTCGAGATGAACAATA |
| sepDKpn_Rv | ACTTATTGGTACCATTACACAATTC |
| tirXhoI_Fw | AAAGGATCTCGAGATGCCTATTGG |
| tirKpn_Rv | CTCACAGGTACCTTTAAACGAAAC |
| cesLXhoI_Fw | CAGAGCCTCGAGATGAATCTTTTA |
| cesLKpnI_Rv | ATTTAAGGGTACCTTCATGATGTC |
| sepLBamHIFw | ATTACGTGAGGATCCATGGCTAAT |
| sepLXhoIstop_Rv | AAAACTCGAGATCACATAACATCC |
| cesTBamHI_Fw | AAGAGAAGGATCCATGTCATCAAG |
| cesTKpnI_Rv | CTAATAAGGTACCTTTATCTTCCG |
Figure 1CesL protein is required for proper control of EPEC T3 secretion. (A) The EPEC wild-type strain (WT), ΔescN mutant strain, and ΔcesL mutant strain (-) carrying an empty vector (pTrc99A_FF4), plasmid pMTcL (cesL) producing untagged CesL or plasmid pMTHcL (his-cesL) producing His-CesL were grown under T3S inducing conditions and the secreted protein content was examined. Protein samples were resolved on SDS-PAGE and stained with Coomassie brilliant blue (CBB). Proteins corresponding to T3SS substrates or the autotransporter EspC (arrowhead) are indicated on the right. Secreted proteins (S) or whole-cell lysates (P) were analyzed by immunoblotting using antibodies against the indicated protein (WB). (B) In-frame deletion of the first gene in the LEE3 operon results in a polar effect. Upper panel. Genetic organization of (1) wild-type cesL gene, (2) ΔcesL Km resistant mutant (3) equivalent CR orf12 deletion mutant in EPEC but with the kanamycin cassette (ΔcesL2::km), (4) the latter mutant without the kanamycin cassette (ΔcesL2). Lower panel. Secreted proteins (S) and whole-cell lysates (P) of EPEC WT, the isogenic mutant ΔescN, and the cesL knock-out mutant with (ΔcesL2::km) or without (ΔcesL2) the kanamycin resistance cassette, and carrying (+) or not (-) pMATcL2HA plasmid expressing CesL-HA. Protein samples were analyzed by CBB-stained SDS-PAGE or immunoblotting with antibodies against the HA tag, the LEE3-encoded protein EscQ or the intracellular housekeeping chaperone DnaK. EspC is indicated with an arrowhead in CBB. (C) The EPEC ΔcesL mutant displays the same secretion phenotype as the ΔsepD and ΔsepL mutants. Protein secretion profile of EPEC WT, ΔescN, ΔsepD, ΔsepL, ΔcesL and the ΔcesLΔsepD and ΔcesLΔsepL double mutants was analyzed by CBB-stained SDS-PAGE (left panel) or by immunoblotting using anti-EspB and anti-Map antibodies (WB, right panel). EspC is indicated with an arrowhead in CBB.
Figure 2CesL associates independently with both SepD and SepL proteins. The MBP-CesL or MBP protein from a cleared cell lysate was immobilized on amylose resin and then a cleared lysate (L) containing either (A) untagged SepD or (B) untagged SepL was loaded onto the protein-coupled resin. Samples from the flow-through (FT), washes (W), and elutions (E) were collected and analyzed by CBB-stained SDS-PAGE and immunoblotting using anti-SepD or anti-SepL polyclonal antibodies. (C) Quantification of β-galactosidase activity of E. coli SU202 strain carrying plasmids pSR659 and pSR658 or derivatives thereof (expressing sepD, sepL, cesL, tir or cesT genes). The known SepD-SepL and CesT-Tir interactions were used as positive controls. Data represent the mean of three independent experiments in Miller units. Measurements were subjected to a 2-sided t-test to determine the statistical significance of the activity produced by the protein interactions compared to their respective negative control. * p < 0.005.
Figure 3CesL and SepL interaction with SepD is required to regulate secretion hierarchy. (A) His-SepL or His-SepLΔ81-94 and (B) MBP-CesL or MBP-CesLCΔ10 recombinant proteins were immobilized on Ni-NTA or amylose resin, respectively, and then a cleared lysate (L) containing untagged SepD was loaded onto the protein-coupled resin. Samples from the flow-through (FT), washes (W) and elutions (E) were collected and analyzed by CBB-stained SDS-PAGE and immunoblotting using anti-SepD antibodies (left panels). S. cerevisiae PJ69-4a/α strain carrying plasmids pGADT7 and pGBKT7 or their indicated derivatives was serially diluted and spotted onto SD-Leu-Trp medium as a growth control, and onto SD-Leu-Trp-His medium to test for protein interactions. The plasmid pairs pGADT7-T/pGBKT7-53 and pGADT7-T/pGBKT7-Lam were used as positive and negative controls, respectively. The plasmid pair pGBKT7-SepD/pGADT7-T was used as a SepD self-activation control (right panels). (C) Secreted proteins from EPEC wild-type strain (WT), ΔescN strain, and ΔsepL (-) or ΔcesL (-) strains harboring an empty vector (pACTrc), plasmid pMATpL expressing SepL, plasmid pMATpLΔ81-94 expressing SepLΔ81-94, plasmid pMATcL expressing CesL or plasmid pMATcLCΔ10 expressing CesLCΔ10, were resolved on CBB-stained SDS-PAGE. Immunoblotting of EspB, EspA and DnaK proteins is shown (WB).
Figure 4Interdependent stability of SepL and CesL proteins. (A) Immunoblotting showing the protein levels of chromosomally encoded SepL-FLAG expressed in wild-type EPEC (WT), ΔcesL mutant, and the ΔcesL strain carrying plasmid pMATcL2HA producing CesL-HA. (B) Immunoblotting showing the protein levels of chromosomally encoded CesL-FLAG in wild-type EPEC (WT), ΔsepL mutant, and the ΔsepL strain carrying plasmid pMATpL expressing untagged SepL. After halting de novo protein synthesis by addition of tetracycline, whole cell samples were collected every 15 min during 105 min. DnaK was used as a protein loading control. Samples were normalized according to the culture OD600 at the time of collection.
Figure 5CesL and SepL associate with the membrane independently of their molecular switch interacting partners. (A) Secreted proteins (S) and whole-cell lysates (P) of wild-type EPEC (WT), ΔescN and ΔcesL strains harboring plasmid pMHcL producing CesL-HA (left panel), or plasmid pJHeH producing EspH-HA (right panel), were subjected to SDS-PAGE and immunoblotting with an anti-HA antibody. The presence of EspB and EspA in the supernatant and that of DnaK in the bacterial pellet was also analyzed by immunoblotting. (B,C) Wild-type EPEC (WT), ΔsepD and ΔsepL strains expressing chromosomally encoded (B) CesL-FLAG or (C) SepL-FLAG. EPEC strains were grown under T3S-inducing conditions and fractionated into cytoplasmic (C) and membrane (M) fractions. Whole-cell lysates (P) were loaded as a control. EscJ and DnaK were used as cytoplasmic and membrane protein controls, respectively. Equal amounts of each fraction were probed using antibodies against the FLAG tag, EscJ, or DnaK.
Figure 6CesL interacts with the export gate components EscV and EscU. MBP-CesL (left panels) or MBP (right panels) was bound to a packed amylose resin and a cleared lysate (L) containing the His-tagged cytoplasmic domain of (A) EscV (EscVC) or (B) EscU (EscUC) and the mixture was loaded into the column. Samples from the flow-through (FT), washes (W) and elutions (E) were collected and analyzed by CBB-stained SDS-PAGE and immunoblotting (WB) using anti-EscVC or anti-EscUC polyclonal antibodies. (C) The His-tagged cytoplasmic domain of EscD (EscDN) did not copurify with MBP-CesL and was used as a negative control.
Figure 7Model for regulation of type III secretion hierarchy. During T3SS assembly, two molecular switches ensure that the different substrates are secreted in a hierarchical order. Stage 1. (i) Early substrates are secreted. At this time, the molecular switch proteins SepL, SepD and CesL (in complex or independently), are associated with the membrane and likely located near the export apparatus. (ii) When the needle reaches its predetermined length, EscP interacts with EscUC, promoting a conformational change that flips the first substrate specificity switch, thereby halting early substrate secretion and allowing (together with the SepL/SepD/CesL complex) middle substrate recognition (see next stage). Stage 2. (iii) The first specificity switching event is transmitted to the EscV export gate component via interactions of the SepL/SepD/CesL heterotrimeric complex with both EscU and EscV. This communication enables middle substrates to be recognized and secreted by the EscV docking platform. (iv) At the same time, EscP bound to SepL sequesters the chaperone-effector CesT/Tir complex. Stage 3. (v) Once the translocation pore has been inserted into the host cell membrane, an activation signal is transmitted to the export apparatus, which results in switch complex dissociation, permitting late substrates binding to EscV and effector translocation. In addition, it has been shown that a drop in calcium concentration dissociates the SepL–EscP interaction, releasing the CesT/Tir complex for docking at EscV.